Last reviewed · How we verify
Ad26.Filo
Ad26.Filo is a Viral vector vaccine Biologic drug developed by Janssen Vaccines & Prevention B.V.. It is currently in Phase 1 development for Ebola.
Ad26.Filo is a viral vector vaccine that targets filoviruses.
Ad26.Filo is a viral vector vaccine that targets filoviruses. Used for Ebola.
-
Baseline phase 1 → approval rate
+9.6pp
Industry-wide phase 1 drugs reach approval ~9.6% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas). -
Anti-infectives pathway favourability
+2.0pp
Microbiological endpoints + non-inferiority designs raise approval rates above baseline. -
Big-pharma sponsor
+3.0pp
Janssen Vaccines & Prevention B.V. is a top-20 pharma sponsor — historical approval rates run ~3pp above average due to scale, regulatory experience, and trial-design quality.
| Regulator | Country | Likely year | Lag vs FDA |
|---|---|---|---|
| FDA | US | 2033–2036 | — |
| EMA | EU | 2034–2037 | +0.7 yr |
| MHRA | GB | 2034–2037 | +0.7 yr |
| Health Canada | CA | 2034–2038 | +0.9 yr |
| TGA | AU | 2034–2038 | +1.2 yr |
| PMDA | JP | 2034–2038 | +1.5 yr |
| NMPA | CN | 2035–2039 | +2.3 yr |
| MFDS | KR | 2034–2038 | +1.4 yr |
| CDSCO | IN | 2034–2039 | +1.8 yr |
| ANVISA | BR | 2035–2039 | +2.3 yr |
Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).
Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.
At a glance
| Generic name | Ad26.Filo |
|---|---|
| Sponsor | Janssen Vaccines & Prevention B.V. |
| Drug class | Viral vector vaccine |
| Target | Filovirus glycoprotein |
| Modality | Biologic |
| Therapeutic area | Infectious Disease |
| Phase | Phase 1 |
Mechanism of action
It uses a replication-deficient adenovirus type 26 as a vector to express the filovirus glycoprotein, eliciting an immune response against filoviruses.
Approved indications
- Ebola
Common side effects
- Pain at injection site
- Fatigue
- Headache
Key clinical trials
- A Safety Trial to Test MVA-BN(R)-Filo and Ad26.ZEBOV Vaccines in Healthy Volunteers (PHASE1)
- A Study to Evaluate the Immunogenicity, Safety and Tolerability of Ad26.ZEBOV and MVA-BN-Filo in Healthy Adult Participants (PHASE3)
- A Study of 2-dose Vaccine Regimen Using 3 Consecutive Lots of Ad26.ZEBOV and MVA-BN-Filo in Adult Participants (PHASE3)
- A Study of 2-dose Vaccination Regimen of Ad26.ZEBOV and MVA-BN-Filo in Infants (PHASE2)
- A Study to Evaluate A Range of Dose Levels of Ad26.ZEBOV and MVA-BN-Filo in Healthy Adult Participants (PHASE3)
- Ad26.ZEBOV, MVA-BN-Filo Vaccination in Children and Adults Previously Vaccinated With Control in the EBOVAC-Salone Study (PHASE2)
- Safety, Tolerability and Immunogenicity Study of 2-dose Heterologous Regimens for Ebola Vaccines Ad26.ZEBOV/MVA-BN-Filo (PHASE2)
- A Study of a 2-dose Ebola Vaccine Regimen of Ad26.ZEBOV Followed by MVA-BN-Filo in Healthy Pregnant Women (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Ad26.Filo CI brief — competitive landscape report
- Ad26.Filo updates RSS · CI watch RSS
- Janssen Vaccines & Prevention B.V. portfolio CI
Frequently asked questions about Ad26.Filo
What is Ad26.Filo?
How does Ad26.Filo work?
What is Ad26.Filo used for?
Who makes Ad26.Filo?
What drug class is Ad26.Filo in?
What development phase is Ad26.Filo in?
What are the side effects of Ad26.Filo?
What does Ad26.Filo target?
Related
- Drug class: All Viral vector vaccine drugs
- Target: All drugs targeting Filovirus glycoprotein
- Manufacturer: Janssen Vaccines & Prevention B.V. — full pipeline
- Therapeutic area: All drugs in Infectious Disease
- Indication: Drugs for Ebola
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing